CSF2 and cancer: In this case, one can expect that therapeutic agents targeting the GM-CSF/Jak/Stat5β signaling pathway (e.g., GM-CSF neutralizing antibodies or Jak kinase inhibitors) lowers transferrin levels specifically in the neutrophil-dominant metastatic microenvironment and inhibits cancer metastasis.